share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股SEC公告 ·  07/12 16:18
Moomoo AI 已提取核心信息
On July 10, 2024, Senti Biosciences, Inc. held its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, known as the Officer Exculpation Amendment. This amendment aligns with recent changes to Delaware law and was previously approved by the Board of Directors, contingent on stockholder approval. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Another significant amendment approved was to effect a reverse stock split of the company's common stock at a ratio to be determined by the Board, within a range from...Show More
On July 10, 2024, Senti Biosciences, Inc. held its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, known as the Officer Exculpation Amendment. This amendment aligns with recent changes to Delaware law and was previously approved by the Board of Directors, contingent on stockholder approval. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Another significant amendment approved was to effect a reverse stock split of the company's common stock at a ratio to be determined by the Board, within a range from 1-for-5 to 1-for-30. The Officer Exculpation Amendment became effective upon its filing with the Secretary of State of Delaware on the date of the Annual Meeting. The meeting saw a turnout of 68.97% of the total number of shares entitled to vote, with the final voting results confirming the approval of the proposed amendments.
2024年7月10日，Senti Biosciences, Inc.召开了2024年股东年会，对几项关键提案进行了投票。股东批准了一项修正案，即修正和重置公司的第二份修正章程，以限制某些官员的责任，称为官员免责修正案。该修正案符合特拉华州近期法律变化的趋势，并获得了董事会的先前批准前提是获得股东的批准。此外，股东批准了KPMG LLP作为独立注册的上市会计事务所，负责截止到2024年12月31日的财年审核工作。另外批准的另一个重要修正案是在董事会确定的区间1股对5股到1股对30股内实行公司普通股的股票合并。官员免责修正案自股东大会日期向特拉华州国务卿提交并生效。会议吸引了总股本中68.97%的股份投票，最终投票结果确认了建议修正案的批准。
2024年7月10日，Senti Biosciences, Inc.召开了2024年股东年会，对几项关键提案进行了投票。股东批准了一项修正案，即修正和重置公司的第二份修正章程，以限制某些官员的责任，称为官员免责修正案。该修正案符合特拉华州近期法律变化的趋势，并获得了董事会的先前批准前提是获得股东的批准。此外，股东批准了KPMG LLP作为独立注册的上市会计事务所，负责截止到2024年12月31日的财年审核工作。另外批准的另一个重要修正案是在董事会确定的区间1股对5股到1股对30股内实行公司普通股的股票合并。官员免责修正案自股东大会日期向特拉华州国务卿提交并生效。会议吸引了总股本中68.97%的股份投票，最终投票结果确认了建议修正案的批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息